Group 1 - As of November 30, 2025, Jiangsu has 717 A-share companies, an increase of 3 from the previous month, ranking third in the country, with Zhejiang Province in second place at 729 companies [3][8] - The total market value of Jiangsu's A-share companies is 85,083.8 billion yuan, a decrease of nearly 2,000 billion yuan from the previous month, but an increase of 17,104 billion yuan year-on-year [3][51] - In terms of city distribution, Suzhou leads with 227 A-share companies, followed by Wuxi with 126 and Nanjing with 124 [8][30] Group 2 - In the first eleven months of 2025, Jiangsu added 24 new A-share companies, ranking first among all provinces, with a total IPO fundraising amount of 158.74 billion yuan, placing third nationally [22][62] - Suzhou's IPO fundraising total reached 68.27 billion yuan, maintaining the top position in the province, while Wuxi, Yangzhou, and Changzhou each exceeded 10 billion yuan [23][30] - Jiangsu's A-share companies are predominantly small to mid-cap, with 309 companies valued between 1 billion and 5 billion yuan, accounting for approximately 43.1% of the total [51] Group 3 - The market value distribution shows that there are 11 companies with a market value over 100 billion yuan, ranking fourth in the country, while 187 companies exceed 10 billion yuan [51][34] - The electronic industry leads in total market value at 13,072.71 billion yuan, followed by the pharmaceutical and biological sector at 10,982.62 billion yuan [37][38] - The A-share market in Jiangsu experienced a general decline in November 2025, with 231 companies seeing price increases and 483 companies experiencing declines [55][52] Group 4 - As of November 30, 2025, Jiangsu has 49 companies in the IPO application queue, ranking third among provinces, with Suzhou leading with 20 applications [58][62] - A total of 231 companies in Jiangsu are in the IPO counseling stage, the highest in the country, with Suzhou having 76 companies [62][60] - The number of companies applying for IPOs has increased, but the number of companies in the queue has decreased significantly [62]

责任编辑：小浪快报 融券方面，丰倍生物12月18日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元。 资料显示，苏州丰倍生物科技股份有限公司位于江苏省常州市金坛区兴河东路19号，成立日期2014年7 月25日，上市日期2025年11月5日，公司主营业务涉及以废弃油脂资源综合利用业务为主,油脂化学品业 务为辅。主营业务收入构成为：废弃资源综合利用业务91.18%，其中:生物基材料79.60%，其中:生物燃 料11.58%，油脂化学品8.66%，其他(补充)0.16%。 截至12月10日，丰倍生物股东户数2.76万，较上期减少50.19%；人均流通股1123股，较上期增加 100.77%。2025年1月-9月，丰倍生物实现营业收入22.51亿元，同比增长62.32%；归母净利润1.17亿元， 同比增长35.32%。 12月18日，丰倍生物跌0.40%，成交额4793.81万元。两融数据显示，当日丰倍生物获融资买入额214.35 万元，融资偿还376.86万元，融资净买入-162.51万元。截至12月18日，丰倍生物融资融券余额合计 9500.6 ...

Core Viewpoint - The company, Fengbei Bio, is a high-tech enterprise in the field of waste resource utilization, primarily focusing on the production of resource-based products from waste oils [1] Group 1: Company Overview - Fengbei Bio has made long-term investments in research and development, continuously expanding the depth and breadth of waste oil resource utilization [1] - The company has established a waste resource recycling industry chain that includes "waste oil - biofuels (biodiesel) - bio-based materials" [1] - The company leverages its core technology in oil fat utilization and channel advantages to provide chemical products derived from oils to its customers [1]

证券日报网讯12月17日，丰倍生物（603334）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东人数为27630户。十大流通股东名单敬请关注公司后续发布的定期报告。 ...

证券日报网讯12月9日晚间，丰倍生物（603334）发布公告称，公司拟使用不超过人民币3亿元(含本数) 的闲置募集资金(含超募资金)进行现金管理，投资安全性高、流动性好的保本型理财产品，现金管理额 度有效期自董事会审议通过之日起12个月之内有效。 ...

格隆汇12月9日丨丰倍生物(603334.SH)公布，公司拟使用不超过人民币1亿元闲置自有资金进行现金管 理，在前述额度内，资金可以循环滚动使用。投资期限内任一时点的交易金额（含前述投资的收益进行 再投资的相关金额）不超过前述额度。 ...

格隆汇12月9日丨丰倍生物(603334.SH)公布，公司拟使用闲置募集资金（含超募资金）不超过人民币3 亿元（含本数）进行现金管理，使用期限为自公司董事会审议通过之日起12个月内。在上述额度及有效 期内，资金可循环滚动使用，期限内任一时点的交易金额（含前述投资的收益进行再投资的相关金额） 不应超过投资额度。 ...

Group 1 - The core point of the article is that Fengbei Bio announced a board meeting to discuss changes in registered capital, company type, and amendments to the articles of association, along with the need for business registration changes [1] - For the first half of 2025, Fengbei Bio's revenue composition is as follows: bio-based materials accounted for 79.6%, biofuels for 11.58%, oleochemical products for 8.66%, and other businesses for 0.16% [1] - As of the report date, Fengbei Bio has a market capitalization of 6.3 billion yuan [1]

国泰海通证券股份有限公司 关于苏州丰倍生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为苏 州丰倍生物科技股份有限公司（以下简称"丰倍生物"、"公司"或"发行人"） 首次公开发行股票并在主板上市的保荐人，根据《证券发行上市保荐业务管理办 法》《上市公司募集资金监管规则》《上海证券交易所股票上市规则》《上海证券 交易所上市公司自律监管指引第 1 号——规范运作》等有关法律法规和规范性文 件的要求，就丰倍生物使用暂时闲置募集资金进行现金管理的事项进行了审慎核 查，并发表如下核查意见: 一、募集资金基本情况 经中国证券监督管理委员会《关于同意苏州丰倍生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2025〕1958 号）核准，公司首次公开发 行股票 3,590.00 万股，每股发行价格为人民币 24.49 元，募集资金总额为人民币 87,919.1000 万元，扣除各项发行费用后实际募集资金净额为人民币 79,443.7747 万元。上述募集资金到位情况已经中兴华会计师事务所（特殊普通合伙）验证， 并由其出具中兴华验字 ...

苏州丰倍生物科技股份有限公司 以募集资金置换预先投入募投项目资金及支付 发行费用的专项说明的鉴证报告 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 目 录 一、鉴证报告 二、以募集资金置换预先投入募投项目资金及支付发行费用的专项说明 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地址（ l o c a t i o n ）： 北 京 市 丰 台 区 丽 泽 路 2 0 号 丽 泽 S O H O B 座 2 0 层 2 0 /F,To wer B, Lize S O H O, 2 0 Lize Ro ad ,F en g tai District,Beijin g P R Ch in a 电话 ...